Streetbeat News

RXRX

Recursion Pharmaceuticals, Inc.

https://www.recursion.com

Industry

Biotechnology

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Open

6.89

Mkt cap

1.7B

Volume

10M

High

6.92

P/E Ratio

-4.23

52-wk high

15.74

Low

6.15

Div yield

N/A

52-wk low

5.88

Recursion (NASDAQ:RXRX) has signed an agreement with Bayer AG to in-license a new chemical entity from their fibrosis research collaboration. This compound has shown potential to reverse fibrotic processes and is now part of Recursion's late discovery pipeline. The company's technology enabled the identification of small molecules that can potentially treat fibrotic diseases, which are a major health concern with high unmet needs.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:01 pm

Ark Invest, led by Cathie Wood, purchased $16.9 million worth of Roku Inc (ROKU) shares, despite recent analyst skepticism about the company's revenue growth and market competition. The shares were bought across multiple Ark ETFs, including ARKF, ARKK, and ARKW. Additionally, Ark sold shares of Coinbase (COIN), Robinhood (HOOD), Exact Sciences (EXAS), and Stratasys (SSYS), while buying shares of Recursion Pharmaceuticals (RXRX) and Rocket Lab USA (RKLB).

Portfolio Pulse from Benzinga Neuro

January 03, 2024 | 2:54 am

Recursion Pharmaceuticals (NYSE:RXRX) has seen a 3.06% increase in short interest since its last report, with 37.02 million shares sold short, representing 26.94% of its float. The short interest is higher than the peer group average of 14.47%. High short interest can indicate bearish market sentiment but can also be bullish if it leads to a short squeeze.

Portfolio Pulse from Benzinga Insights

January 01, 2024 | 1:15 pm

Recursion Pharmaceuticals has partnered with Enamine to create screening libraries using Recursion's MatchMaker protein-ligand interaction predictions. These libraries will be designed from Enamine's vast library of 36 billion compounds, focusing on up to 100 biological targets. Enamine will have the option to sell these libraries to customers and will co-brand them under both Enamine and MatchMaker trademarks.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:01 pm

Recursion Pharmaceuticals (NYSE:RXRX) has seen a 7.4% increase in short interest since the last report, with 35.50 million shares shorted, representing 25.83% of its float. The short interest is higher than the peer group average of 13.79%. High short interest can indicate bearish market sentiment but can also be bullish if it leads to a short squeeze.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 4:45 pm

Cathie Wood's Ark Invest sold 251,419 shares of Roku Inc. (ROKU) worth approximately $21.11 million through its ARK Innovation ETF (ARKK). This sale followed Roku's Q3 revenue exceeding expectations. Ark also sold DraftKings Inc (DKNG) shares and bought shares in Pacific Biosciences (PACB), Intellia Therapeutics (NTLA), 10X Genomics (TXG), Recursion Pharmaceuticals (RXRX), and Iridium Communications (IRDM), indicating a strategic adjustment of its portfolio.

Portfolio Pulse from Benzinga Neuro

November 14, 2023 | 3:18 am

JP Morgan analyst Eric Joseph has maintained a Neutral rating on Recursion Pharmaceuticals (NASDAQ:RXRX) but has lowered the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:03 pm

Needham analyst Gil Blum maintains a 'Buy' rating on Recursion Pharmaceuticals (NASDAQ:RXRX), but lowers the price target from $17 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:56 pm

Bayer and Recursion have announced a research collaboration focusing on oncology. The partnership will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry, as well as Recursion's AI-guided drug discovery platform.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:44 pm

Recursion (NASDAQ:RXRX) has announced a data collaboration deal with Tempus Labs, an ambition to build a top 50 supercomputer powered by NVIDIA (NASDAQ:NVDA), and an updated focus of collaboration with Bayer in precision oncology. Recursion will pay Tempus up to $160M over the next five years for access to one of the world's largest proprietary oncology datasets. The company also plans to quadruple its supercomputing power with NVIDIA's support. Additionally, Recursion and Bayer will initiate up to seven oncology programs, with Recursion eligible to receive up to $1.5 billion plus royalties on net sales.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.